- JP-listed companies
- Other
(4893) Other
Market cap
¥6.4B
P/E ratio
Develops cancer immunotherapy treatments for solid tumors using proprietary PRIME technology that enhances immune cell activation and generates revenue through both in-house drug development and technology licensing.
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Return on Assets | - | - | - | - | -8.7 | -5.4 | -3.3 | -4.3 |
| Return on equity (%) | - | - | - | |||||
| Employees | 7 | 8 | 12 | 14 | 19 | 28 | 25 | 23 |